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We report on the phenomenon of protein-accelerated catalysis in the ﬁeld of artiﬁcial metalloenzymes based on the non-covalent
incorporation of biotinylated rhodium–diphosphine complexes in (strept)avidin as host proteins. By incrementally varying the
[Rh(COD)(Biot-1)]+ vs. (strept)avidin ratio, we show that the enantiomeric excess of the produced acetamidoalanine decreases
slowly. This suggests that the catalyst inside (strept)avidin is more active than the catalyst outside the host protein. Both avidin
and streptavidin display protein-accelerated catalysis as the protein embedded catalyst display 12.0- and 3.0-fold acceleration over
the background reaction with a catalyst devoid of protein. Thus, these artiﬁcial metalloenzymes display an increase both in activity
and in selectivity for the reduction of acetamidoacrylic acid.
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ganic chemistry; Protein-accelerated catalysis1. Introduction
Enantioselective catalysis is one of the most eﬃcient
ways to synthesize high-added value enantiomerically
pure organic compounds [1]. In recognition for their
pioneering accomplishments in transition metal medi-
ated enantioselective catalysis, the 2001 Nobel Prize in
chemistry was awarded to Knowles [2], Noyori [3] and
Sharpless [4].
As the subtle details which govern enantioselection
cannot be reliably predicted or computed, catalysis relies
more and more on a combinatorial approach. In the
past couple of years, several groups have made impor-
tant contributions in this ﬁeld [5].
Biocatalysis oﬀers an attractive alternative for the
synthesis of enantiopure products [6]. In many aspects,* Corresponding author. Tel.: +41 32 718 2516; fax: +41 32 718
2511.
E-mail address: thomas.ward@unine.ch (T.R. Ward).enzymatic catalysis is complementary to transition met-
al-based systems, although the scope of reactions is lim-
ited to enzymatic processes. From a combinatorial
perspective however, the potential of directed evolution
techniques in optimizing an enzymes selectivity is
unrivalled [7].
We have recently demonstrated that incorporation of
an achiral rhodium–diphosphine moiety into a protein
environment can yield highly enantioselective hydrogen-
ation catalysts [8].
Inspired by the seminal work of Kaiser [9,10], several
groups have developed methods to covalently modify
proteins by incorporating transition-metal catalysts to
yield hybrid catalytic systems with promising properties
[7,10].
The approach we follow relies on non-covalent (i.e.,
supramolecular) interactions between the metal catalyst
and the protein. As no chemical coupling step is re-
quired upon addition of the catalyst precursor to the
protein, the integrity of organometallic species is
Scheme 2.
2warranted [11]. As suggested by Whitesides, the biotin–
avidin system [12] oﬀers an attractive scaﬀold to perform
such experiments [13,14].
The principle of the biotin–avidin technology (often
referred to as molecular velcro) relies on the extraordi-
nary aﬃnity of biotin for either avidin or streptavidin
(Ka  1014 M1) [12]. Most importantly, it is generally
accepted that derivatization of the valeric acid side chain
of biotin does not aﬀect signiﬁcantly the strength of the
biotin–avidin interaction as most stabilizing contacts are
located on the bicyclic framework of (+)-biotin [12]. In
the past twenty years, the biotin–avidin technology has
found numerous applications in various ﬁelds of bio-
technology including ELISA, immunolabeling, aﬃnity
targeting, drug delivery etc. [12]. In the context of this
work, it should be emphasized that both avidin and
streptavidin are tetrameric proteins constituted by four
identical subunits which can bind up to four biotin mol-
ecules with no binding cooperativity.
Performing the reduction of acetamidoacrylic acid
in avidin as host protein, the rhodium coenzyme
[Rh(COD)(Biot-1)]+ aﬀords (S)-acetamidoalanine in
quantitative yield with 39% ee.
As the catalyst devoid of its protein environment
yields essentially racemic product under identical condi-
tions, we reasonned that it is imperative to ensure that
catalysis proceeds exclusively within the protein
(Scheme 1). As avidin possesses an isoelectric point
pI = 10.4, we speculated that at pH 7.0, the cationic cat-
alyst may display a signiﬁcantly reduced aﬃnity for the
positively charged avidin. The modest ee may thus be a
reﬂection of two competing catalytic cycles:
(i) inside the protein which aﬀords an highly enantio-
enriched product;
(ii) outside the protein which aﬀords racemic product.
Streptavidin, which displays only 30% sequence
homology with avidin possesses a much lower isolectric
point (pI = 6.4) [12]. Using streptavidin may thus solveScheme 1.the problem of Coulomb repulsion between the host
protein and the cationic catalyst precursor. The reaction
performed under identical conditions aﬀorded (R)-ace-
tamidoalanine in nearly quantitative yield with 94% ee
[8]. Upon lowering the pH to 4.0, the reaction proceeded
quantitively (Scheme 2).2. Results and discussion
Both in the ﬁelds of homogeneous [15] and heteroge-
neous [16] catalysis, the concept of ligand acceleration
has proven very valuable. In ligand-accelerated cataly-
sis, the addition of a ligand increases the reaction rate
of a catalytic transformation which proceeds even in
the absence of added ligand.
In the area of artiﬁcial metalloenzymes, the same con-
cept may apply as the ‘‘coenzyme’’ [Rh(COD)(Biot-1)]+
was shown to be active (and unselective) in the absence
of host protein (Scheme 1). As the interaction between
the biotinylated moiety and the host protein is non-
covalent, it is inherently reversible. The amount bound
and free catalyst (abbreviated lbound and lfree, respec-
tively) is determined by the stability constant of the
supramolecular ediﬁce [Rh(COD)(Biot-1)]+–(strept)avi-
din and the individual concentrations (We use Lehns
notation for host–guest interactions [17]; (strept)avidin
denotes both avidin and streptavidin) [18]. Because of
the very low solubility of acetamidoacrylate, we could
not perform a thorough kinetic analysis to determine
the individual rate constants kcat–prot and kcat for the
reaction within the protein and outside the protein,
respectively. Assuming that both competing catalytic
cycles (within and outside (strept)avidin) proceed
according to the same mechanism, we reasonned that
we could determine the relative rates kcat–prot:kcat by
3incrementally varying the [Rh(COD)(Biot-1)]+ to (str-
ept)avidin ratio. By plotting the enantiomeric excess of
the product as a function of this ratio, it is should be
possible to estimate the extent of protein-acceleration
(Fig. 1).
Hydrogenation experiments were performed using
both avidin and streptavidin loaded with varying
amounts of [Rh(COD)(Biot-1)]+. The [Rh(COD)(Biot-
1)]+-to-protein ratio was varied incrementally from 1:1
to 10:1 and the enantiomeric excess is plotted against
this ratio, Fig. 1. The reactions were performed as de-
scribed in [8]. Two noteworthy features emerge:
(i) protein acceleration and
(ii) cooperativity between the four catalytic sites.
(i) Both avidin and streptavidin display protein accel-
erated catalysis. The extent of protein acceleration in
streptavidin (where the (R)-product is produced prefer-
entially) can be estimated by
%ðRÞcalculated ¼
kcat–prot  lbound  aþ kcat  lfree  b
kcat–prot  lbound þ kcat  lfree
; ð1Þ
where kcat–prot and kcat are the rate constants for the
reaction within the protein and outside the protein,
respectively, lbound and lfree are the number of pro-
tein-bound complexes ([Rh(COD)(Biot-1)]+–(strept)avi-
din) and protein-free [Rh(COD)(Biot-1)]+ moieties; a
and b are the % (R) produced by [Rh(COD)(Biot-1)]+–
(strept)avidin and by [Rh(COD)(Biot-1)]+, respectively.Fig. 1. Enantioselectivity as a function of the [Rh(COD)(Biot-1)]+-to-
(strept)avidin ratio. The triangles correspond to the ee (R enantiomer)
obtained with streptavidin as host protein; the squares correspond to
the ee (S enantiomer) obtained with avidin as host protein. The broken
lines represent the theoretical ee with no protein acceleration,
emphasizing the eﬀect of the protein on the rate of the reduction.As this procedure produces a single equation with two
unknowns kcat–prot and kcat, we can only extract the ratio
rather than the individual rate constants.
If no protein acceleration is operative, kcat–prot = kcat.
At eight equivalents [Rh(COD)(Biot-1)]+ vs. protein,
lbound = lfree = 4 as (strept)avidin possesses four bind-
ing sites. Since a = 0.97 (i.e., 94% ee (R) for [Rh(COD)
(Biot-1)]+–streptavidin) and b = 0.50 (racemic material
produced by [Rh(COD)(Biot-1)]+), the % (R) predicted
at eight equivalents and with no protein acceleration is
% (R) = 73.5 (i.e., 47% ee (R)). The broken lines in
Fig. 1 correspond to the ee calculated with no protein
acceleration, assuming that both reactions proceed
according to the same mechanism.
By performing a least square minimization on the cal-
culated and measured % ee for a given kcat–prot:kcat ratio,
we estimate the relative rates. For streptavidin and avi-
din, we compute a kcat–prot:kcat ratio of 2.95 and 11.96,
respectively.
(ii) Increasing the [Rh(COD)(Biot-1)]+-to-protein ra-
tio from 1:1 to 4:1 (i.e., all four biotin binding sites occu-
pied) leads to a slight increase in enantioselectivity (from
89% to 94% ee (R) for streptavidin and from 34% to 39%
(S) for avidin). This suggests that there is a slight coop-
erativity on the enantioselectivity between the four bio-
tin binding sites.3. Conclusion
By incrementally varying the [Rh(COD)(Biot-1)]+-to-
(strept)avidin ratio, we have unraveled the phenomenon
of protein-accelerated catalysis, similar to ligand accel-
erated catalysis. We have shown that the hydrogenation
of acetamidoacrylic acid within artiﬁcial metalloenzyme
proceeds at a faster rate than the corresponding hydro-
genation outside of the protein.
We believe that this phenomenon is caused by the
aﬃnity of the hydrophobic substrate for the hydropho-
bic catalytic pocket within the host protein. Although
the ‘‘active site’’ was by no means optimized to accomo-
date an enantioselective hydrogenation event, it is pleas-
ing to witness an increase both in activity and in
selectivity for this reaction, prototypical of the homoge-
neous catalysis kingdom. Current eﬀorts in the group
are directed towards the determination of individual rate
constants using a more soluble substrate.Acknowledgements
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